EXEL Exelixis Inc.

$29.125 +0.47%

1,655,563 Shares Traded
2,668,365 Average Volume (last 30 days)

as of February 22, 2018 EST IEX Real-Time Price

Short Pain Metrics

Approximate Amount of Money Shorts Have Lost on the Day: $2.18 million
If Intiated on the First, Shorts Have Realized a Year to Date Return of:7.68%
If Intiated One Month Ago, Shorts Have Realized a Return of:1.53%
If Initiated Five Days ago, Shorts Have Realized a Return of:1.86%
Peer Potential Short Squeezes Near Real Time Screener
*Please note the actual returns of shorts could be different as they started from different points

Daily Indicators

Daily Short Pain Indicator [i] - Always Use Fundamentals on EverythingNeutral
200 Day Moving Average Indicator Bullish
50 Day Moving Average Indicator Bearish
52 Week High/Low Indicator Neutral

Short Stats

Short Percent to Float 5.55%
Short Interest16.14 million
Float291.01 million
Short Ratio5.28
Market Cap$8.58 billion
Market Maker ActivityDaily Short Volume

News

02-15-2018
3 Things In Biotech You Should Learn Today: February 14, 2018 (SeekingAlpha)
02-14-2018
Exelixis to Present at the RBC Capital Markets Global Healthcare Conference on February 21, 2018 (Business Wire)
02-13-2018
Exelixis Announces Results from a Phase 2 Investigator-Sponsored Trial of Cabozantinib in the First-Line Treatment of Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma (Business Wire)
02-10-2018
3 Things In Biotech You Should Learn Today: February 9, 2018 (SeekingAlpha)
02-09-2018
Key events next week - healthcare (SeekingAlpha)
02-08-2018
Exelixis to Release Fourth Quarter and Full Year 2017 Financial Results on Monday, February 26, 2018 (Business Wire)
02-08-2018
Your Daily Pharma Scoop: Abeona Surges, Gilead Results, Biogen Setback (SeekingAlpha)
02-07-2018
Exelixis' Cabometyx shows treatment benefit in early-stage genitourinary tumor study; shares up 1% (SeekingAlpha)
02-07-2018
Exelixis Announces Updated Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Refractory Genitourinary (GU) Tumors (Business Wire)
02-06-2018
Exelixis to Present at the Leerink Partners Global Healthcare Conference on February 14 (Business Wire)


Smart Money Sentiment

Institutional Ownership (Top 15 Funds) 88.4%

Earnings Stats

PE Ratio 57.06
Dividend Yield 0%
Peer EarningsEarnings Calendar

Technicals

200 Day Moving Average $26.02
50 Day Moving Average $29.21
52 Week High $32.5
52 Week Low $18.03



Data provided for free by IEX. Questions? Read the FAQ